Study: Antidepressants reduce mortality by 35% in patients with diabetes

Antidepressants reduce deaths by more than a third in patients with diabetes and depression, according to a study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.

People with diabetes are two to three times more likely to have depression than people without diabetes, according to the U.S. Centers for Disease Control and Prevention. Half to three-quarters of people with diabetes and depression go undiagnosed, despite therapy and medicine being very effective.

The incidence of major depressive disorder amongst individuals with diabetes is significantly greater than the general population. Diabetes and depression each independently contribute to increasing total mortality."

Study's corresponding author, Vincent Chin-Hung Chen, Professor, of Chiayi Chang Gung Memorial Hospital and Chang Gung University in Puzi, Taiwan

In this large population-based study, researchers used the National Health Insurance Research Database in Taiwan to identify 53,412 patients diagnosed with diabetes and depression since 2000. The researchers followed this population until 2013 to see if antidepressants reduced the death rate. They found that antidepressants significantly reduced mortality by 35 percent.

"This data provides further rationale for the screening and treating of depression in persons who have diabetes," Chen said.

Source:
Journal reference:

Chen, V. et al. (2019) Antidepressants reduced risk of mortality in patients with diabetes mellitus: a population-based cohort study in Taiwan. Journal of Clinical Endocrinology & Metabolism. doi.org/10.1210/jc.2018-02362.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study shows oral semaglutide matches DPP-4i in adherence and persistence for type 2 diabetes